DHA-PC tablet as well as preparation method and application thereof

The tablets made by extracting DHA-PC powder from herring fish roe combined with sodium carboxymethylcellulose and microcrystalline cellulose were solved, and the renal abnormalities in mice induced by CTX were significantly reduced, and the serum index and inflammatory factors were significantly reduced. Improve antioxidant enzyme activity and improve renal function.

CN119055603APending Publication Date: 2024-12-03ZHEJIANG OCEAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410940429.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

As an anti-tumor drug, cyclophosphamide (CTX) has a great side effects caused by drug-induced liver and renal tissue damage and bone marrow and immune system damage caused by its metabolite, and no research on improving renal function abnormalities in mice has been reported.

Method used

Design a DHA-PC tablet, made of equal amounts of transfer tablets to improve CTX by extracting DHA-PC powder from herring roe and combining with sodium carboxymethylcellulose and microcrystalline cellulose. Induced renal abnormalities in mice.

Benefits of technology

It significantly reduces the levels of BUN and CRE in mice when renal function is abnormal, reduces the secretion of proinflammatory factors, increases the secretion of anti-inflammatory factors, improves the activity of endogenous antioxidant enzymes in the kidneys, improves renal abnormalities, and provides new therapeutic ideas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055603A_ABST
    Figure CN119055603A_ABST
Patent Text Reader

Abstract

The invention relates to DHA-PC (docosahexaenoic acid-polycarbonate) tablets as well as a preparation method and application thereof, 250 tablets comprise the following components by weight: 0.2 g of DHA-PC powder, 48.8 g of compressible powder, 0.5 g of sodium carboxymethyl cellulose and 0.5 g of microcrystalline cellulose. The DHA-PC tablet prepared by the preparation method disclosed by the invention is simple in preparation method, can effectively improve CTX-induced mouse renal dysfunction, can remarkably reduce the secretion of proinflammatory factors and remarkably improve the secretion of anti-inflammatory factors when the mouse renal dysfunction occurs, and can remarkably reduce the MDA content when the mouse renal dysfunction occurs; the activity of endogenous antioxidant enzyme in the kidney is remarkably improved, and a new treatment thought is provided for treatment of renal dysfunction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural medicines, and in particular relates to a DHA-PC tablet and a preparation method and application thereof. Background Art

[0002] DHA-PC is a phosphatidylcholine type DHA, a special marine phospholipid rich in DHA and EPA. Its molecular structure is combined with DHA through an acetyl group. The acetyl residues in DHA-PC from different sources are different. Therefore, DHA-PC is not a single component compound, but a class of compounds.

[0003] Cyclophosphamide (CTX) is a spectrum alkylating anti-tumor drug that is widely used in clinical practice. It is effective for symptoms such as solid tumors. However, the toxicity of its metabolite acrolein can cause drug-induced liver and kidney tissue damage in patients treated, which is mainly manifested as increased serum transaminase and decreased antioxidant function of liver and kidney tissues. Long-term use can cause irreversible damage to the bone marrow and immune system of patients treated. CTX has large side effects and a high mortality rate.

[0004] At present, the research on the combination of DHA and PC mainly focuses on its better ability to improve memory, eliminate brain fatigue, enhance concentration and attention, etc., while there are no reports on the effect of DHA-PC in improving CTX-induced renal dysfunction in mice. Summary of the invention

[0005] In view of the problems existing in the prior art, the purpose of the present invention is to provide a DHA-PC tablet and a preparation method and application thereof, which are specifically achieved through the following technical solutions:

[0006] A DHA-PC tablet, calculated as 250 tablets, contains the following components by weight:

[0007] DHA-PC powder 0.2g, compressible powder 48.8g, sodium carboxymethyl cellulose 0.5g, microcrystalline cellulose 0.5g.

[0008] A DHA-PC tablet, characterized in that the DHA-PC powder is prepared by the following steps:

[0009] 1) obtaining herring roe freeze-dried powder by thawing, homogenizing and vacuum freeze drying;

[0010] 2) adding anhydrous ethanol to the herring roe freeze-dried powder, and performing a first reaction in a 60° C. water bath under magnetic stirring, after centrifugation, adding anhydrous ethanol to the precipitate again, and reacting again in a 60° C. water bath under magnetic stirring, and collecting two ethanol extracts;

[0011] 3) The extract was subjected to reduced pressure distillation at 70°C to remove ethanol, and then pre-cooled acetone was added to remove neutral oils and free fatty acids, the acetone phase was discarded, and the bottom extract was obtained after centrifugation, and DHA-PC powder was obtained after vacuum freeze drying.

[0012] Furthermore, in step 2), the mass ratio of herring roe powder to anhydrous ethanol in the first reaction is 1:10, and the reaction time is 1 hour; the mass ratio of the two in the second reaction is 1:8, and the reaction time is 30 minutes.

[0013] Furthermore, the centrifugation conditions in step 2) are: 12000 rpm, 10 min.

[0014] A preparation method of DHA-PC tablets adopts an equal amount addition method, firstly mixing a formula amount of DHA-PC powder with compressible starch, then adding a formula amount of sodium carboxymethyl cellulose and microcrystalline cellulose, mixing evenly, and putting the mixture into a rotary tablet press for direct tableting to obtain DHA-PC tablets.

[0015] Application of the DHA-PC tablets prepared by the preparation method in improving cyclophosphamide-induced abnormal renal function in mice.

[0016] Furthermore, the abnormal renal function includes one or more of renal capsule rupture, renal tubular stenosis, partial shedding of proximal tubular cells, and separation and irregular arrangement of distal tubular cells, accompanied by inflammatory cell infiltration.

[0017] Furthermore, this application can significantly reduce the levels of serum indicators BUN and CRE in mice with abnormal renal function.

[0018] Furthermore, the application can significantly reduce the secretion of pro-inflammatory factors and significantly increase the secretion of anti-inflammatory factors when the kidney function of mice is abnormal. The pro-inflammatory factors include one or more of IL-6, IL-1β and TNF-α, and the anti-inflammatory factor is IL-10.

[0019] Furthermore, the application can significantly reduce the MDA content in mice with abnormal renal function and significantly increase the activity of endogenous antioxidant enzymes in the kidneys, wherein the endogenous antioxidant enzymes include one or more of SOD, CAT and GSH-Px.

[0020] The DHA-PC tablets prepared by the preparation method of the present invention have a simple preparation method, and the prepared tablets can effectively improve CTX-induced abnormal renal function in mice, can significantly reduce the secretion of pro-inflammatory factors when the renal function of mice is abnormal and significantly increase the secretion of anti-inflammatory factors, significantly reduce the MDA content when the renal function of mice is abnormal, and significantly increase the activity of endogenous antioxidant enzymes in the kidney, thereby providing a new treatment idea for the treatment of abnormal renal function. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Effects of DHA-PC on renal function indices of mice ((A) serum BUN level; (B) serum BUN level; (C) renal KIM-1 level; (D) renal Cys-C level);

[0022] Figure 2 Effects of DHA-PC on the levels of inflammatory factors in the kidneys of mice ((A) kidney IL-10 level; (B) kidney IL-6 level; (C) kidney IL-1β level; (D) kidney TNF-α level);

[0023] Figure 3 Effects of DHA-PC on renal oxidative stress in mice ((A) renal MDA activity; (B) renal CAT activity; (C) renal SOD activity; (D) renal GSH-Px level);

[0024] Figure 4 The effect of DHA-PC on renal tissue pathology (400 times). DETAILED DESCRIPTION

[0025] The present invention is further described below in conjunction with specific embodiments to facilitate a better understanding of the present technical solution.

[0026] Example 1

[0027] Preparation of DHA-PC powder: An appropriate amount of herring roe is thawed, homogenized, and vacuum freeze-dried to obtain herring roe freeze-dried powder. Herring roe powder is reacted with anhydrous ethanol (m / m=1:10) in a 60°C water bath with magnetic stirring for 1 hour. After the first centrifugation (12000rpm, 10min), anhydrous ethanol at 1:8 (m / m) is added to the precipitate and reacted for another 30min in a 60°C water bath with magnetic stirring. Two ethanol extracts are collected, most of the ethanol is removed by reduced pressure distillation at 70°C, and 1-2 times the volume of pre-cooled acetone is added to remove neutral oils and free fatty acids, the acetone phase is discarded, and the bottom extract is obtained after centrifugation. After vacuum freeze drying, DHA-PC powder is obtained, in which the content of DHA and EPA is 242mg / g and 88mg / g, and the content of PC is 461mg / g.

[0028] Example 2

[0029] Preparation of DHA-PC tablets: Using the equal amount dropping method, first mix 0.2g of the extracted DHA-PC powder with 48.8g of compressible starch, then add 0.5g of sodium carboxymethyl cellulose and 0.5g of microcrystalline cellulose, mix well, put into a rotary tablet press and directly compress to obtain 250 tablets.

[0030] Test Case

[0031] The DHA-PC tablets prepared in Example 2 were subjected to quality inspection. Each inspection method was carried out according to the operating methods in the Chinese Pharmacopoeia. The test indicators included tablet weight difference inspection, friability inspection, disintegration time inspection and activity evaluation.

[0032] Test Example 1: Tablet Weight Difference Check

[0033] Take 20 complete marine DHA-PC tablets, accurately weigh the total weight of the 20 tablets and the weight of each tablet, and calculate the average tablet weight. Compare the calculated average with the weight of each tablet. If the number of tablets outside the weight difference range is less than two and none of them exceeds one time of the weight difference limit, the tablet weight difference test can be considered qualified.

[0034] The results of the intra-chip difference check are shown in Table 1.

[0035] Table 1: Results of weight difference test of marine DHA-PC tablets

[0036]

[0037] The results of the tablet weight difference test of marine DHA-PC tablets are shown in Table 1. The calculation results show that the average tablet weight of marine DHA-PC tablets is 0.198g. In this way, the minimum tablet weight difference is 0.183 to 0.213g (when the average tablet weight is less than 0.30g, the weight difference limit is ±7.5%), so none of the above 20 tablets exceeds the tablet weight difference limit. In summary, the tablet weight difference test results of marine DHA-PC tablets meet the standards.

[0038] Test Example 2: Friability Check

[0039] The friability test of DHA-PC tablets was conducted using a tablet four-in-one instrument. The specific method is as follows: Take 15 complete DHA-PC tablets, blow off the powder adhering to the tablets, and weigh them accurately. Then place the DHA-PC tablets in a cylinder, and stop the cylinder after rotating it 100 times. Take out all the tablets in the cylinder, blow off the broken and fallen powder caused by the rotation of the cylinder, and weigh the remaining tablets accurately again. Finally, we compare the final weight with the initial weight. When the weight reduction does not exceed 1% and there are no cracks, breaks or crushed tablets, the tablet can be considered to meet the requirements.

[0040] Weigh 15 intact tablets and measure their total weight to be 3.003g. After the friability test of the marine DHA-PC tablets, blow away the powder on the surface of the tablets, and then weigh the tablets. The total weight of the tablets is 2.999g, and the weight reduction is 0.13% (<1%). There are no cracks, breaks or crushed tablets, so the friability test of the marine DHA-PC tablets is qualified.

[0041] Test Example 3: Disintegration Time Limit Inspection

[0042] The disintegration time of marine DHA-PC tablets was measured using a tablet four-in-one instrument. The specific operation method is: after adjusting the water temperature in the lifting disintegrator to 37±1℃, take 6 intact marine DHA-PC tablets and put them into the basket of the disintegrator, turn on the instrument and start timing. When the marine DHA-PC tablets in the basket are broken into small particles and leak out of the screen, stop timing, and the timing time is the disintegration time of the DHA-PC tablets.

[0043] After taking 6 pieces of marine DHA-PC tablets and adding them into the basket of the smart tablet four-in-one instrument, the equipment was started and the timing was started. When the tablets were broken into fine particles and flowed out of the screen, the timing was stopped and the disintegration time was measured to be 3 minutes and 43 seconds, which was much less than 15 minutes. Therefore, the disintegration time of the marine DHA-PC tablets also met the requirements.

[0044] Verification Example

[0045] Activity evaluation steps:

[0046] 1) Mouse model establishment: Male ICR mice (n=32, 6 weeks old, 15-17 g) were provided by the Zhejiang Animal Experiment Public Service Platform (Hangzhou Ziyuan Experimental Animal Technology Co., Ltd.). The animal experiments were approved by the Animal Ethics Committee of Zhejiang Ocean University (license No.

[0047] 2023004). All mice were housed in an SPF animal room with standard humidity (60±5%), temperature (23±2℃), and a 12-h light / dark cycle. After one week of adaptive feeding, the mice were randomly divided into three groups (n=8), including the CON group (0.9% saline), the MOD group (CTX, 80 mg / kg), and the DHA-PC group (DHA-PC preparation, 100 mg / kg).

[0048] First, mice in the CON group were intraperitoneally injected with 0.1 mL of 0.9% saline, and mice in the other groups were intraperitoneally injected with the same volume of 80 mg / kg CTX for 5 consecutive days. From the 6th day, the CON group and the MOD group were gavaged with 0.1 mL of 0.9% saline, and the DHA-PC group was gavaged with the same amount of 100 mg / kg DHA-PC preparation for 7 consecutive days. During the experiment, the feed intake, water intake, and weight changes of the mice were monitored and recorded daily. At the end of the feeding, all mice were killed by cervical dislocation, blood was collected through the eye sockets, and the intact kidneys were separated and stored at -80°C for further study.

[0049] 2) Determination of biochemical indices in mice: The collected blood samples were centrifuged (6000x g, 4°C, 10min) to obtain serum. The levels of CRE and BUN in serum were determined using a kit. An appropriate amount of mouse kidney tissue and normal saline were homogenized at a ratio of 1:9, centrifuged (6000x g, 4°C, 10min), and the tissue supernatant was obtained. The levels of KIM-1, Cys-C, IL-6, IL-10, IL-1β and TNF-α in the homogenate of kidney tissue were determined using ELISA kits. The levels of MDA and the activities of CAT, SOD, and GSH-Px in kidney tissue were also detected.

[0050] 3) Pathological analysis of mouse kidney tissue: The intact kidney tissue was fixed with 4% paraformaldehyde solution and embedded in paraffin, cut into 5 μm sections, and stained with H&E. The pathological changes of kidney tissue were observed under an optical microscope (Olympus, CX31RTSF).

[0051] Activity evaluation results

[0052] Effects of DHA-PC tablets on renal function indices in CTX mice: Serum BUN and CRE are often used to assess the degree of renal damage. Figure 1As shown in the results, CTX induced a significant increase in serum BUN and CRE levels in mice (BUN: 13.81±0.25mmol / L vs 9.29±0.18mmol / L; CRE: 20.36±0.97μmol / L vs 14.74±1.05μmol / L; p<0.01), indicating that CTX caused severe renal insufficiency in mice. The levels of both in the DHA-PC group were significantly lower than those in the MOD group (p<0.01). In addition, compared with the CON group, the levels of KIM-1 and Cys-C, sensitive indicators of early renal dysfunction, were significantly increased in the MOD group (KIM-1: 114.12±2.25ng / mL vs 40.39±1.59ng / mL; Cys-C: 2461.09±51.42pg / mL vs 1594.23±23.30pg / mL; p<0.01). After DHA-PC treatment, the above indicators of mice were significantly reduced (p<0.01), which indicates that DHA-PC can improve CTX-induced renal dysfunction to a certain extent.

[0053] Effects of DHA-PC tablets on renal inflammation levels in CTX mice: Figure 2 , CTX promoted the secretion of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in the kidney and inhibited the secretion of anti-inflammatory cytokines (IL-10), indicating that CTX stimulated the inflammatory response in the mouse kidney. However, after oral administration of DHA-PC, the level of IL-10 (1718.93±67.30pg / mL vs 950.71±21.04pg / mL, p<0.01) in the mouse kidneys was significantly increased, while the levels of IL-6 (592.65±7.64pg / mL vs 642.66±13.99pg / mL, p<0.01), IL-1β (76.61±2.05pg / mL vs 167.52±4.10pg / mL, p<0.01) and TNF-α (107.14±2.76pg / mL vs 199.93±4.76pg / mL, p<0.01) were significantly decreased, indicating that DHA-PC can improve CTX-induced renal injury by regulating the expression of inflammatory factors.

[0054] Effects of DHA-PC tablets on renal oxidative stress in CTX mice: The expression of endogenous antioxidant enzymes (SOD, CAT, GSH-Px) and MDA content in the kidneys were detected to reflect the regulatory effect of DHA-PC on antioxidant capacity. Figure 3As shown in the results, compared with the CON group, the activities of SOD, CAT and GSH-Px in the MOD group were significantly decreased, and the content of MDA was significantly increased (P<0.01), indicating that CTX disturbed the redox balance of the mouse kidney. DHA-PC treatment significantly reduced the expression of MDA (2.40±0.04nmol / mg prot vs 3.81±0.23nmol / mg prot, p<0.01), and increased the activities of CAT (50.74±0.91U / mg prot vs 17.96±0.62U / mg prot, p<0.01), SOD (14.14±0.31U / mg prot vs 5.28±0.23U / mg prot, p<0.01) and GSH-Px (505.55±9.26U / mg prot vs 172.46±2.55U / mg prot, p<0.01). These results suggest that DHA-PC can alleviate CTX-induced oxidative stress in mice by improving antioxidant indices. Effect of DHA-PC tablets on renal histopathology in CTX mice: To further investigate the effects of CTX on the extent of renal damage in mice and the repairing effect of DHA-PC, H&E staining was used to evaluate the histological changes in the kidneys. Figure 4 As shown in the figure, there were no obvious signs of damage in the kidneys of mice in the CON group. However, CTX caused serious damage to the kidneys of mice, including rupture of the renal capsule, stenosis of the renal tubule lumen, partial shedding of proximal tubular cells, and separation and irregular arrangement of distal tubular cells, accompanied by inflammatory cell infiltration. After DHA-PC intervention, the nephron structure basically returned to normal. The glomerular structure was clear, the proximal and distal tubular structures were normal, and no obvious inflammatory cell infiltration was observed in the interstitium. In summary, DHA-PC can improve CTX-induced renal injury.

Claims

1. A DHA-PC tablet, Features Based on 250 tablets, it contains the following components by weight: DHA-PC powder 0.2g, compressible powder 48.8g, sodium carboxymethyl cellulose 0.5g, microcrystalline cellulose 0.5g.

2. A DHA-PC tablet as claimed in claim 1, Features The DHA-PC powder is prepared by the following steps: 1) obtaining herring roe freeze-dried powder by thawing, homogenizing and vacuum freeze drying; 2) adding anhydrous ethanol to the herring roe freeze-dried powder, and performing a first reaction in a 60° C. water bath under magnetic stirring, after centrifugation, adding anhydrous ethanol to the precipitate again, and reacting again in a 60° C. water bath under magnetic stirring, and collecting two ethanol extracts; 3) The extract was subjected to reduced pressure distillation at 70°C to remove ethanol, and then pre-cooled acetone was added to remove neutral oils and free fatty acids, the acetone phase was discarded, and the bottom extract was obtained after centrifugation, and DHA-PC powder was obtained after vacuum freeze drying.

3. A DHA-PC tablet as claimed in claim 2, Features In step 2), the mass ratio of herring roe powder to anhydrous ethanol in the first reaction is 1:10, and the reaction time is 1h; the mass ratio of the two in the second reaction is 1:8, and the reaction time is 30min.

4. A DHA-PC tablet as claimed in claim 2, Features The centrifugation condition in step 2) is: 12000 rpm, 10 min.

5. A method for preparing a DHA-PC tablet, Features The preparation method adopts an equal amount addition method, firstly mixing a formula amount of DHA-PC powder with compressible starch, then adding a formula amount of sodium carboxymethyl cellulose and microcrystalline cellulose, mixing evenly, and then putting the mixture into a rotary tablet press for direct tablet compression to obtain DHA-PC tablets.

6. Use of the DHA-PC tablet according to any one of claims 1 to 5 in improving cyclophosphamide-induced renal dysfunction in mice.

7. The use according to claim 6, It is characterized in that The renal function abnormality includes one or more of renal capsule rupture, renal tubular stenosis, partial shedding of proximal tubular cells, and separation and irregular arrangement of distal tubular cells, accompanied by inflammatory cell infiltration.

8. The use according to claim 6, It is characterized in that This application can significantly reduce the levels of serum indicators BUN and CRE in mice with abnormal renal function.

9. The use according to claim 6, It is characterized in that The application can significantly reduce the secretion of pro-inflammatory factors and significantly increase the secretion of anti-inflammatory factors when the kidney function of mice is abnormal. The pro-inflammatory factors include one or more of IL-6, IL-1β and TNF-α, and the anti-inflammatory factor is IL-10.

10. The use according to claim 6, It is characterized in that The application can significantly reduce the MDA content in mice with abnormal renal function and significantly increase the activity of endogenous antioxidant enzymes in the kidneys. The endogenous antioxidant enzymes include one or more of SOD, CAT and GSH-Px.